EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 40 (Novembre 2024) Hors série n° 1 Med Sci (Paris), 40 (2024) 52-55 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 40, Novembre 2024
Les Cahiers de Myologie
Page(s) 52 - 55
Section Prix SFM
DOI https://doi.org/10.1051/medsci/2024162
Publié en ligne 18 novembre 2024
  1. Koch J, Gärtner S, Li CM, et al. Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase: Identification of the First Molecular Lesion Causing Farber Disease. J Biol Chem 1996 ; 271 (51) : 33110–5. [CrossRef] [PubMed] [Google Scholar]
  2. Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol 1979 ; 6 (3) : 227–31. [CrossRef] [PubMed] [Google Scholar]
  3. Zhou J, Tawk M, Tiziano FD, et al. Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1. Am J Hum Genet 2012 ; 91 (1) : 5–14. [CrossRef] [PubMed] [Google Scholar]
  4. Yu FPS, Amintas S, Levade T, et al. Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet J Rare Dis 2018 ; 13. [PubMed] [Google Scholar]
  5. Kleynerman A, Rybova J, Faber ML, et al. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions. Biomolecules 2023 ; 13 (2) : 274. [CrossRef] [PubMed] [Google Scholar]
  6. Gebai A, Gorelik A, Li Z, et al. Structural basis for the activation of acid ceramidase. Nat Commun 2018 ; 9 (1) : 1621. [CrossRef] [PubMed] [Google Scholar]
  7. Ferlinz K, Kopal G, Bernardo K, et al. Human Acid Ceramidase: Processing, Glycosylation, and Lysosomal Targeting. J Biol Chem 2001 ; 276 (38) : 35352–60. [CrossRef] [PubMed] [Google Scholar]
  8. Ehlert K, Frosch M, Fehse N, et al. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 2007 ; 5 : 15. [CrossRef] [PubMed] [Google Scholar]
  9. Lee BH, Mongiovi P, Levade T, et al. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report. Am J Med Genet A 2020 ; 182 (10) : 2369–71. [CrossRef] [PubMed] [Google Scholar]
  10. Puma A, Ezaru A, Cavalli M, et al. A case of ASAH1-related pure SMA evolving into adult-onset Farber disease. Clin Genet 2021 ; 100 (2) : 234–5. [CrossRef] [PubMed] [Google Scholar]
  11. Antonarakis SE, Valle D, Moser HW, et al. Phenotypic variability in siblings with Farber disease. J Pediatr 1984 ; 104 (3) : 406–9. [CrossRef] [PubMed] [Google Scholar]
  12. Alayoubi AM, Wang JCM, Au BCY, et al. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med 2013 ; 5 (6) : 827–42. [CrossRef] [PubMed] [Google Scholar]
  13. Sikora J, Dworski S, Jones EE, et al. Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities. Am J Pathol 2017 ; 187 (4) : 864–83. [CrossRef] [PubMed] [Google Scholar]
  14. Yu FPS, Sajdak BS, Sikora J, et al. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment. Am J Pathol 2019 ; 189 (2) : 320–38. [CrossRef] [PubMed] [Google Scholar]
  15. Beckmann N, Kadow S, Schumacher F, et al. Pathological manifestations of Farber disease in a new mouse model. Biol Chem 2018 ; 399 (10) : 1183–202. [CrossRef] [PubMed] [Google Scholar]
  16. Nagree MS, Rybova J, Kleynerman A, et al. Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency. Commun Biol 2023 ; 6 : 560. [CrossRef] [PubMed] [Google Scholar]
  17. Ehlert K, Levade T, Di Rocco M, et al. Allogeneic hematopoietic cell transplantation in Farber disease. J Inherit Metab Dis 2019 ; 42 (2), 286–294. [CrossRef] [PubMed] [Google Scholar]
  18. Guffon N, Bertrand Y, Forest I, et al. Bone Marrow Transplantation in Children with Hunter Syndrome: Outcome after 7 to 17 Years. J Pediatr 2009 ; 154 (5) : 733–7. [CrossRef] [PubMed] [Google Scholar]
  19. Walia JS, Neschadim A, Lopez-Perez O, et al. Autologous Transplantation of Lentivector/Acid Ceramidase–Transduced Hematopoietic Cells in Nonhuman Primates. Hum Gene Ther 2011 ; 22 (6) : 679–87. [CrossRef] [PubMed] [Google Scholar]
  20. Boespflug-Tanguy O, Sevin C, Piguet F. Gene therapy for neurodegenerative disorders in children: dreams and realities. Archives de Pédiatrie 2023 ; 30 (8, Supplement 1) : 8S32–40. [CrossRef] [Google Scholar]
  21. Ellison S, Parker H, Bigger B. Advances in therapies for neurological lysosomal storage disorders. J Inherit Metab Dis 2023 ; 46 (5) : 874–905. [CrossRef] [PubMed] [Google Scholar]
  22. He X, Dworski S, Zhu C, et al. Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clin 2017 ; 7 : 85–96. [CrossRef] [PubMed] [Google Scholar]
  23. Parini R, Deodato F. Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int J Mol Sci 2020 ; 21 (8) : 2975. [CrossRef] [PubMed] [Google Scholar]
  24. Zhang H, Nagree MS, Liu H, et al. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis. Gene Ther 2023 ; 30 (3) : 297–308. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.